As Catalent prepares to join Novo family, CDMO's sales continue to slide

As Catalent gets ready to join the Novo fold, the contract manufacturing juggernaut continues to slide on its diminishing COVID-19 business.

In the second quarter of Catalent’s 2024 fiscal year, which covers the three-month period that ended Dec. 31, the company reported revenues of $1.03 billion. That sum was down 11% in constant currencies from the $1.15 billion the company nabbed for the same period the prior year. Catalent pointed to a “decline in demand for COVID-19 related programs” as the reason for the revenue slump.